{"originalText": "，缘于入院前1月于我院诊为乙状结肠癌，于2015-05-03在全麻上行腹腔镜上乙状结肠根治性切除术，术后病理（201614352），示：“乙状结肠浸润性管状腺癌I-II级，侵及浆膜上层。手术标本下、上切端及另送（下切端）、（上切端）均未见癌浸润。找到肠周淋巴结10个，及另送的（直肠下动脉根部）淋巴结3个，均未见癌转移。，免疫组化：KI-67（20%+），CK7（+），CK20（+++），VILLIN（++++），CDX2（+++），β-CATENIN（膜+++）。该病例未检测到KRAS基因12、13号密码子热点突变。，病理：该病例未检测到BRAF基因V600E突变”，术后给予对症、营养支持等治疗，恢复良好,伤口愈合II/甲。2016.06.03予“奥沙利铂200MGIVGTTD1+卡培他滨1500MGPOBIDD2-14”方案化疗1个疗程，辅以止吐、保肝、制酸、增强免疫等治疗，无明显化疗毒副反应。此次为行上一周期化疗，门诊拟乙状结肠癌术后化疗收入院。下次出院以来精神、睡眠、饮食可，无腹痛、腹胀、发热，大小便正常，体重较前无明显变化。", "entities": [{"label_type": "疾病和诊断", "overlap": 0, "start_pos": 13, "end_pos": 18}, {"end_pos": 49, "label_type": "手术", "overlap": 0, "start_pos": 35}, {"label_type": "疾病和诊断", "overlap": 0, "start_pos": 69, "end_pos": 85}, {"end_pos": 130, "label_type": "解剖部位", "overlap": 0, "start_pos": 125}, {"end_pos": 150, "label_type": "解剖部位", "overlap": 0, "start_pos": 138}, {"end_pos": 332, "label_type": "药物", "overlap": 0, "start_pos": 328}, {"end_pos": 349, "label_type": "药物", "overlap": 0, "start_pos": 345}, {"end_pos": 382, "label_type": "解剖部位", "overlap": 0, "start_pos": 381}, {"label_type": "疾病和诊断", "overlap": 0, "start_pos": 418, "end_pos": 425}, {"end_pos": 449, "label_type": "解剖部位", "overlap": 0, "start_pos": 448}, {"end_pos": 452, "label_type": "解剖部位", "overlap": 0, "start_pos": 451}]}
